Low pretreatment total testosterone (< 3 ng/mL) predicts extraprostatic disease in prostatectomy specimens from patients with preoperative localized prostate cancer.
about
Testosterone Replacement Therapy and Prostate Cancer IncidenceTestosterone and prostate cancer: an evidence-based review of pathogenesis and oncologic riskLow pretreatment serum total testosterone is associated with a high incidence of Gleason score 8-10 disease in prostatectomy specimens: data from ethnic Chinese patients with localized prostate cancer.Low serum total testosterone level as a predictor of upstaging and upgrading in low-risk prostate cancer patients meeting the inclusion criteria for active surveillance.Poor glycemic control of diabetes mellitus is associated with higher risk of prostate cancer detection in a biopsy population.Is there a protective role of testosterone against high-grade prostate cancer? Incidence and severity of prostate cancer in 553 patients who underwent prostate biopsy: a prospective data register.Controversies on individualized prostate cancer care: gaps in current practice.LHRH and LHR genotypes and prostate cancer incidence and survival.Testosterone in prostate cancer: the Bethesda consensus.Testosterone Therapy Among Prostate Cancer Survivors.Low serum testosterone predicts upgrading and upstaging of prostate cancer after radical prostatectomy.Low testosterone level is an independent risk factor for high-grade prostate cancer detection at biopsy.Preoperative low serum testosterone is associated with high-grade prostate cancer and an increased Gleason score upgrading.Preoperative sex steroids are significant predictors of early biochemical recurrence after radical prostatectomy.Low serum testosterone is a predictor of high-grade disease in patients with prostate cancer.The relationship between prostate-specific antigen and TNM classification or Gleason score in prostate cancer patients with low prostate-specific antigen levels.Study of testosterone as a predictor of tumor aggressiveness in patients with prostate cancer.Testosterone Levels Correlate With Grade Group 5 Prostate Cancer: Another Step Toward Personalized Medicine.
P2860
Q26771774-201CF277-A8DC-42AD-ABDF-F10B845C4A70Q26775766-4F0DC07A-94E6-46BE-B78B-EB89662E2448Q30565173-87B821B9-3AF2-431F-9920-C9FD4BD71F34Q33566981-181F3EED-DDC9-41CB-8F5A-FE89F90B4983Q34149590-733F6EEA-C028-47DD-B0CF-DE336C9C8557Q36304676-43C71263-7787-4E0D-A620-1C5C8236745CQ37149085-67DBF45B-53BA-4B4A-8F6B-2A5CF20E3B88Q37367217-90519C91-5475-48B1-B201-7F50E04C412CQ37963010-EEFAC0A3-E728-4238-BEB2-D94D20B5DAF8Q38913362-75D5FFC9-1D99-4F22-B2F5-67FD6A1373EDQ40144303-D53D9D75-7BCE-4B1C-877F-D56DCDA1C635Q40289446-A7FF4135-D984-4E2E-9EBC-1D3C66BBC7DFQ40463189-5DA3C59A-517D-48F1-A6F7-E6AD38CAA1ECQ46990159-0C6C5EA7-94B5-477F-817E-284F343016A0Q47700604-84DD71A1-D5B6-4AE7-9247-6466867845ECQ50580241-7E00DBE2-A2DE-4B5C-8293-ECA4E9926519Q50985557-921AA22E-E32D-4C50-A1B0-A3FD5973484CQ52996349-A5F11251-DF9F-4181-A80C-50069FCF8E27
P2860
Low pretreatment total testosterone (< 3 ng/mL) predicts extraprostatic disease in prostatectomy specimens from patients with preoperative localized prostate cancer.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
2010年學術文章
@zh
2010年學術文章
@zh-hant
name
Low pretreatment total testost ...... ive localized prostate cancer.
@en
Low pretreatment total testosterone
@nl
type
label
Low pretreatment total testost ...... ive localized prostate cancer.
@en
Low pretreatment total testosterone
@nl
prefLabel
Low pretreatment total testost ...... ive localized prostate cancer.
@en
Low pretreatment total testosterone
@nl
P2093
P2860
P1433
P1476
Low pretreatment total testost ...... ive localized prostate cancer.
@en
P2093
Alban Fabre
Alexandre de la Taille
Andras Hoznek
Claude Clément Abbou
Dimitri Vordos
Evanguelos Xylinas
Guillaume Ploussard
Laurent Salomon
Xavier Durand
Yves Allory
P2860
P304
P356
10.1111/J.1464-410X.2010.09816.X
P577
2010-11-02T00:00:00Z